Genfit S.A. (OTCMKTS:GNFTF) Sees Significant Increase in Short Interest

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 15,500 shares, an increase of 1,622.2% from the March 15th total of 900 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Genfit Price Performance

GNFTF opened at $3.54 on Tuesday. The business has a 50 day moving average of $3.54 and a 200-day moving average of $4.36. Genfit has a 12-month low of $2.95 and a 12-month high of $5.55.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.